Retinoic acid receptor-α (RARA); promyelocytic leukemia (PML); histone deacetylase (HDAC) BriefCommunication Pages: 365 - 365
Ubiquitin specific peptidase 9 X-linked (USP9X; FAF); v-ets erythroblastosis virus E26 oncogene homolog (ERG) BriefCommunication Pages: 372 - 372
Calcium release–activated calcium channel (CRAC); stromal interaction molecule 1 (STIM1); transmembrane protein 142A (ORAI1; TMEM142A; CRACM1) BriefCommunication Pages: 377 - 377
CC chemokine receptor 2 (CCR2; CD192); monocyte chemoattractant protein-1 (MCP-1; CCL2) BriefCommunication Pages: 379 - 379
Bioluminescent mouse model of HPV+ oral tumors to track the effect of therapeutics BriefCommunication Pages: 381 - 381
Mouse model of dominant Ullrich congenital muscular dystrophy (UCMD) BriefCommunication Pages: 382 - 382
Engineered, zinc finger domain–containing recombinases for site-specific delivery of therapeutic genes BriefCommunication Pages: 383 - 383
Crystal structure of metabotropic glutamate receptor subtype 1 (mGluR1; GRM1) BriefCommunication Pages: 384 - 384
Mouse cardiomyocytes generated from fibroblasts with one pluripotency factor and four small molecules BriefCommunication Pages: 386 - 386
Multiplexed ion beam imaging (MIBI) for detection of up to 100 target proteins in clinical samples BriefCommunication Pages: 387 - 387
Fluorescent antibodies to membrane-bound tumor necrosis factor (mTNF) as a predictive biomarker for therapeutic responders BriefCommunication Pages: 388 - 388